

## WO9914313

Publication Title:

BIOLOGICAL SYSTEMS FOR MANUFACTURE OF  
POLYHYDROXYLALKANOATE POLYMERS CONTAINING 4-HYDROXYACIDS

Abstract:

The gene encoding a 4-hydroxybutyryl-Co A transferase has been isolated from bacteria and integrated into the genome of bacteria also expressing a polyhydroxyalkanoate synthase, to yield an improved production process for 4HB-containing polyhydroxyalkanoates using transgenic  
416

organisms, including both bacteria and plants. The new pathways provide means for producing 4HB containing PHAs from cheap carbon sources such as sugars and fatty acids, in high yields, which are stable. Useful strains are obtained by screening strains having integrated into their genomes a gene encoding a 4HB-CoA transferase and/or PHA synthase, for polymer production. Processes for polymer production use recombinant systems that can utilize cheap substrates. Systems are provided which can utilize amino acid degradation pathways, alpha -ketoglutarate, or succinate as substrate.

-----  
Data supplied from the esp@cenet database - <http://ep.espacenet.com>

*This Patent PDF Generated by Patent Fetcher(TM), a service of Stroke of Color, Inc.*

Patent provided by Sughrue Mion, PLLC - <http://www.sughrue.com>

**BEST AVAILABLE COPY**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 9/10, 15/54, 15/70, C12R 1/19,</b> <b>C12P 1/04, 7/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/14313</b> <b>(43) International Publication Date:</b> 25 March 1999 (25.03.99)
<b>(21) International Application Number:</b> PCT/US98/19659 <b>(22) International Filing Date:</b> 18 September 1998 (18.09.98)  <b>(30) Priority Data:</b> 60/059,373 19 September 1997 (19.09.97) US  <b>(71) Applicant:</b> METABOLIX, INC. [US/US]; 303 Third Street, Cambridge, MA 02142 (US).  <b>(72) Inventors:</b> HUISMAN, Gjal't, W.; Apartment 1F, 52 Salem Street, Boston, MA 02113 (US). SKRALY, Frank, A.; Apartment 5, 39 Bay State Road, Boston, MA 02215 (US). MARTIN, David, P.; 33 Hemlock Street, Arlington, MA 02174 (US). PEOPLES, Oliver, P.; 27 Radcliffe Road, Arlington, MA 02174 (US).  <b>(74) Agents:</b> PABST, Patrea, L. et al.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished          upon receipt of that report.</i>
<b>(54) Title:</b> BIOLOGICAL SYSTEMS FOR MANUFACTURE OF POLYHYDROXYALKANOATE POLYMERS CONTAINING 4-HYDROXYACIDS  <b>(57) Abstract</b> <p>The gene encoding a 4-hydroxybutyryl-Co A transferase has been isolated from bacteria and integrated into the genome of bacteria also expressing a polyhydroxyalkanoate synthase, to yield an improved production process for 4HB-containing polyhydroxyalkanoates using transgenic organisms, including both bacteria and plants. The new pathways provide means for producing 4HB containing PHAs from cheap carbon sources such as sugars and fatty acids, in high yields, which are stable. Useful strains are obtained by screening strains having integrated into their genomes a gene encoding a 4HB-CoA transferase and/or PHA synthase, for polymer production. Processes for polymer production use recombinant systems that can utilize cheap substrates. Systems are provided which can utilize amino acid degradation pathways, <math>\alpha</math>-ketoglutarate, or succinate as substrate.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**BIOLOGICAL SYSTEMS FOR MANUFACTURE OF  
POLYHYDROXYALKANOATE POLYMERS  
CONTAINING 4-HYDROXYACIDS**

Background of the Invention

5           This application claims priority to U.S. Serial No. 60/059,373  
filed September 19, 1997, entitled Biological Systems for the Manufacture  
of Polyhydroxyalkanoate Polymers containing 4-Hydroxyacids by Gjalt  
W. Huisman, Frank A. Skraly, David P. Martin, and Oliver P. Peoples.

10           Poly [(R)-3-hydroxyalkanoates] (PHAs) are biodegradable and  
biocompatible thermoplastic materials, produced from renewable  
resources, with a broad range of industrial and biomedical applications  
(Williams and Peoples, 1996, CHEMTECH 26, 38-44). In recent years,  
what was viewed as a single polymer, poly- $\beta$ -hydroxybutyrate (PHB), has  
evolved into a broad class of polyesters with different monomer  
15       compositions and a wide range of physical properties. To date around  
one hundred different monomers have been incorporated into the PHA  
polymers (Steinbüchel and Valentin, 1995, FEMS Microbiol. Lett. 128;  
219-228). It has been useful to broadly divide the PHAs into two groups  
according to the length of their side chains and their pathways for  
20       biosynthesis. Those with short side chains, such as polyhydroxybutyrate  
(PHB), a homopolymer of R-3-hydroxybutyric acid units,



25           where:  $n$  is 0 or an integer and  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ , and  $\text{R}^4$  are each  
selected from saturated and unsaturated hydrocarbon  
radicals; hal- and hydroxy-substituted radicals; hydroxy  
radicals; halogen radicals; nitrogen-substituted radicals;  
oxygen-substituted radicals; and hydrogen atoms,

are crystalline thermoplastics, whereas PHAs with long side chains are  
more elastomeric. The former have been known for about seventy years  
30       (Lemoigne & Roukhelman, 1925), whereas the latter materials were first

identified in the early 1980's (deSmet *et al.*, 1983, *J. Bacteriol.*, 154: 870-878). Before this designation, however, PHAs of microbial origin containing both (*R*)-3-hydroxybutyric acid and one or more long side chain hydroxyacid units containing from five to sixteen carbon atoms had  
5 been identified (Steinbüchel and Wiese, 1992, *Appl. Microbiol. Biotechnol.* 37: 691-697; Valentin *et al.*, 1992, *Appl. Microbiol. Biotechnol.* 36: 507-514; Valentin *et al.*, 1994, *Appl. Microbiol. Biotechnol.* 40: 710-716; Lee *et al.*, 1995, *Appl. Microbiol. Biotechnol.* 42: 901-909; Kato *et al.*, 1996, *Appl. Microbiol. Biotechnol.* 45: 363-  
10 370; Abe *et al.*, 1994, *Int. J. Biol. Macromol.* 16: 115-119; Valentin *et al.*, 1996, *Appl. Microbiol. Biotechnol.* 46: 261-267; U.S. Patent 4,876,331). A combination of the two biosynthetic pathways probably provide the hydroxyacid monomers. These latter copolymers can be referred to as PHB-co-HX. Useful examples of specific two-component  
15 copolymers include PHB-co-3-hydroxyhexanoate (Brandl *et al.*, 1989, *Int. J. Biol. Macromol.* 11: 49-55; Amos and McNerey, 1991, *Arch. Microbiol.* 155: 103-106; Shiotani *et al.*, 1994, U.S. patent 5,292,860). Chemical synthetic methods have also been used to prepare racemic PHB copolymers of this type for applications testing (WO 95/20614, WO  
20 95/20615 and WO 96/20621).

Numerous microorganisms have the ability to accumulate intracellular reserves of PHA polymers. Since polyhydroxyalkanoates are natural thermoplastic polyesters, the majority of their applications are as replacements for petrochemical polymers currently in use for packaging  
25 and coating applications. The extensive range of physical properties of the PHA family of polymers, in addition to the broadening of performance obtainable by compounding and blending as traditionally performed in the polymer industry, provides a corresponding broad range of potential end-use applications. The PHAs can be produced in a wide  
30 variety of types depending on the hydroxyacid monomer composition (Steinbüchel and Valentin, 1995, *FEMS Microbiol. Lett.* 128: 219-228). This wide range of polymer compositions reflects an equally wide range

of polymer physical properties including: a range of melting temperatures from 40°C-180°C, glass transition temperatures from -35 to 5°C, degrees of crystallinity of 0% to 80% coupled with the ability to control the rate of crystallization and elongation to break of 5 to 500%. Poly(3-hydroxybutyrate), for example, has characteristics similar to those of polypropylene while poly(3-hydroxyoctanoate) (a copolymer of (*R*)-3-hydroxyoctanoate and (*R*)-3-hydroxyhexanoate) types behave more as elastomers and PHAs with longer side chains giving behavior closer to waxes. The PHAs can also be plasticized and blended with other polymers or agents. One particularly useful form is as a latex of PHA in water.

The monomer compositions also affect solubility in organic solvents allowing for a choice of a wide range of solvents. Copolymers of (*R*)-3-hydroxybutyrate and other hydroxyacid comonomers have significantly different solubility characteristics from those of the PHB homopolymer.

To date, PHAs have seen limited commercial availability with only the copolymer poly(3-hydroxybutyrate-*co*-3-hydroxyvalerate) (PHBV) being available in significant quantities. This copolymer has been produced by fermentation of the bacterium *Ralstonia eutropha* (formerly *Alcaligenes eutrophus*). Fermentation processes for other PHAs have been developed (Williams and Peoples, 1996, CHEMTECH 26: 38-44). Plant crops are also being genetically engineered to produce these polymers, and offer a cost structure in line with the vegetable oils and direct price competitiveness with petroleum based polymers (Williams and Peoples 1996, CHEMTECH 26: 38-44). More traditional polymer synthesis approaches have also been examined, including direct condensation and ring-opening polymerization of the corresponding lactones (Jesudason and Marchessault, 1994, Macromolecules 27: 2595-2602, US 5,286,842; US 5,563,239; U.S. patent No. 5,516,883; U.S. patent No. 5,461,139; Canadian patent application 2,006,508).

Synthesis of PHA polymers containing the monomer 4-hydroxybutyrate (PHB4HB, Doi, Y. 1995, Macromol. Symp. 98, 585-599) or 4-hydroxyvalerate and 4-hydroxyhexanoate containing PHA polyesters have been described (Valentin et al., 1992, Appl. Microbiol. Biotechnol. 36: 507-514 and Valentin et al., 1994, Appl. Microbiol. Biotechnol. 40: 710-716). These polyesters have been manufactured using methods similar to that originally described for PHBV in which the microorganisms are fed a relatively expensive non-carbohydrate feedstock in order to force the incorporation of the monomer into the PHA polyester. For example, production of PHB4HB has been accomplished by feeding glucose and 4-hydroxybutyrate or substrate that is converted to 4-hydroxybutyrate to *A. eutrophus* (Kunioka, M., Nakamura, Y., and Doi, Y. 1988, Polym. Commun. 29: 174; Doi, Y., Segawa, A. and Kunioka, M. 1990, Int. J. Biol. Macromol. 12: 106; Nakamura, S., Doi, Y. and Scandola, M. 1992, Macromolecules 25: 423), *A. latus* (Hiramitsu, M., Koyama, N. and Doi, Y. 1993, Biotechnol. Lett. 15: 461), *Pseudomonas acidovorans* (Kimura, H., Yoshida, Y. and Doi, Y. 1992, Biotechnol. Lett. 14: 445) and *Comomonas acidovorans* (Saito, Y. and Doi, Y., 1994, Int. J. Biol. Macromol. 16: 18). Substrates that are converted to 4-hydroxybutyrate are 1,4-butanediol, 1,6-hexanediol, 1,8-octanediol, 1,10-decanediol, 1,12-dodecanediol and 1,4-butyrolactone. The PHB4HB copolymers can be produced with a range of monomer compositions which again provides a range of polymer properties. In particular as the amount of 4HB increases above 10 wt.%, the melting temperature ( $T_m$ ) decreases below 130°C and the elongation to break increases above 400% (Saito, Y., Nakamura, S., Hiramitsu, M. and Doi, Y., 1996, Polym. Int. 39: 169).

The formation of 4HB containing polymers has also been studied with recombinant strains in studies aimed at improved PHB-4HB formation in *Ralstonia eutropha* or *E. coli*. Mutants of *R. eutropha* H16 were selected that cannot use 4-hydroxybutyrate as a carbon source. When such mutants were tested for copolymer formation, up to 84% 4HB

was incorporated into the accumulated PHA (Kitamura S and Y. Doi, 1994. *in* Biodegradable Plastics and Polyesters, 12, p. 373-378). By introducing additional copies of the *phb* genes, the accumulation of PHB-4HB was enhanced (Lee, Y.-H., Park, J.-S. and Huh, T.-L. 1997, 5 Biotechnol. Lett. 19: 771-774).

It is desirable to develop more cost effective ways of producing PHAs containing 4HB by biological systems. Several factors are critical for economic production of PHA: substrate costs, fermentation time, and efficiency of downstream-processing. A general characteristic of the 10 above described bacteria is that their growth rate is low, they are often difficult to break open and their amenity to genetic engineering is limited. Therefore, processes have been developed that improve the economics of PHA production by using transgenic organisms. Formation of PHB4HB was achieved in *E. coli* using the 4-hydroxybutyrate pathway from *C. kluyveri* (Hein, S., Söhling, B., Gottschalk, G., and Steinbüchel, A. 15 1997. FEMS Microbiol. Lett. 153: 411-418). In these studies both the 4-hydroxybutyryl-CoA transferase and PHA synthase were plasmid encoded. Subsequent work showed that the 4-hydroxybutyrate pathway from *C. kluyveri* supports formation of PHB-4HB in *E. coli* up to 50% of 20 the cell dry weight from glucose as sole carbon source, and where 2.8% of the monomers is 4HB. The 4HB monomer in these strains is most likely derived from succinate, an intermediate of the TCA cycle (Valentin, H.E. and Dennis, D. 1997. J. Biotechnol. 58: 33-38). These studies were based on *Escherichia coli* as recombinant production 25 organisms and PHA biosynthetic genes from PHA producers such as *R. eutropha*.

It is an object of the present invention to provide recombinant processes whereby additional genes can be introduced in transgenic PHB producers to create new strains that synthesize monomers, such as 4HB, 30 for alternative PHAs.

A further object of the present invention is to provide techniques and procedures to stably engineer transgenic organisms that synthesize

PHAs containing 4-hydroxybutyrate either as sole constituent or as co-monomer.

It is also an object of the present invention to provide screening systems for new 4-hydroxybutyryl CoA transferase encoding genes.

- 5 It is another object of the present invention to provide techniques and procedures to engineer new pathways in biological systems for the endogenous synthesis of alternative PHA monomers.

#### Summary of the Invention

- Improved production processes for 4HB containing PHAs using  
10 transgenic strains have been developed. Transgenic *E. coli* strains are described in which the required *phb* genes have been integrated on the chromosome. Additional genes for the synthesis of the 4HB monomer are also integrated on the chromosome. The latter genes can be derived from a broad range of organisms which carry a 4-hydroxybutyryl-CoA transferase  
15 and be identified by screening for this activity in the engineered *E. coli* strains described here. In addition, an endogenous *E. coli* activity is disclosed that can be further improved for the purpose of 4HB-CoA transferase activity. New pathways are also disclosed for the supply of intermediates of 4HB biosynthetic pathways such as  $\alpha$ -ketoglutarate and  $\gamma$ -  
20 aminobutyrate. The diversity of these pathways is important for the successful production of 4HB containing PHAs from cheap carbon sources such as sugars and fatty acids.

#### Brief Description of the Drawings

- Figure 1A is the alignment of the *C. kluyveri* OrfZ sequence with the  
25 N-terminal sequence and internal sequences of 4-hydroxybutyryl CoA transferase (4HBCT) from *C. aminobutyricum* (SEQ ID Nos 1 and 2). Identical residues are indicated, similar residues are indicated by \*. Figures 1B and 1C are the nucleotide sequence of the *orfZ* gene from *C. kluyveri*. Figure 1D is the amino acid sequence of the *orfZ* gene from *C. kluyveri*.  
30 Figure 2 is a schematic of the endogenous synthesis of 4-hydroxybutyryl CoA from  $\alpha$ -ketoglutarate through the GABA shunt. 1.  $\alpha$ -ketoglutarate aminotransferase; 2. glutamate decarboxylase; 3. GABA

transaminase; 4. Succinic semialdehyde reductase; 5. 4-hydroxybutyryl CoA transferase.

Figure 3 is a schematic of the endogenous synthesis of 4-hydroxybutyryl-CoA from GABA precursors. GABA is an intermediate in the degradation of amino acids such as arginine, glutamine and proline. Genes in arginine degradation are encoded by *speA*, *adi*, *speB*, *pat* and *prp*; genes in glutamine degradation are encoded by *gltBD* and *gadB*, genes in proline degradation are encoded by *putA* and *gadB*. GABA is converted to 4-hydroxybutyryl-CoA by the gene products of *gabT*, *4hbD* and *hbcT*.

Figure 4 is a schematic of the endogenous synthesis of 4-hydroxybutyryl CoA from succinate. 1. succinyl CoA-CoA transferase; 2. succinate semialdehyde dehydrogenase; 3. 4-hydroxybutyrate dehydrogenase; 4. 4-hydroxybutyryl CoA transferase.

Figure 5 is a schematic of the construction of plasmids for integration of the PHB synthase (*phbC*) gene from *Z. ramigera* into the chromosome of *E. coli* and other Gram-negative bacteria.

Figures 6 and 6A are a schematic of the construction of plasmids for integration of 3-ketoacyl-CoA thiolase (*phbA*) and acetoacetyl-CoA reductase (*phbB*) genes from *Z. ramigera* into the chromosome of *E. coli* and other Gram-negative bacteria.

Figure 7 is a schematic of the metabolic and genetic representation of the engineered biosynthetic pathway for 4-hydroxybutyryl-CoA synthesis. The gene products of *gabT*, *4hbD* and *hbcT* are required for this pathway, *gadAB* and *gdhA* are helpful, whereas the gene products of *aspC*, *sad* and *gabD* are preferably absent or inactive.

Figure 8 is a schematic of the construction of plasmids pMSX-TD and pMSXTp1-TD, which expresses enzymes to convert  $\alpha$ -ketoglutarate to 4-hydroxybutyryl-CoA.

Figure 9 is a schematic of the construction of plasmids pMSX-ABT, pMSXTp1-ABT and pMSXTp1-BT, which expresses enzymes to convert  $\alpha$ -ketoglutarate to 4-hydroxybutyryl-CoA.

Figure 10 is a schematic of the construction of plasmid pMSX-ABT and pMSX-ABT-TD which expresses enzymes to convert  $\alpha$ -ketoglutarate to 4-hydroxybutyryl-CoA.

Figure 11 is a schematic of the construction of plasmid pMSX-T1DD which expresses enzymes to convert succinate to 4-hydroxybutyryl-CoA

#### Detailed Description of the Invention

The minimal biological requirement for the synthesis of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) have been defined. Enzymatic synthesis of the substrates for PHA synthase from *R. eutropha* was achieved by incubation of equimolar amounts of (R)-3-hydroxybutyrate and 4-hydroxybutyrate with 4-hydroxybutyrate CoA transferase. *In situ* monomer-CoA synthesis coupled by direct enzymatic polymerization results in the formation of a PHB-4HB copolymer as determined by  $^1\text{H}$ -NMR of the resulting polymer. Techniques and procedures to engineer transgenic organisms that synthesize PHAs containing 4-hydroxybutyrate either as sole constituent or as co-monomer have been developed. In these systems the transgenic organism is either a bacterium eg. *Escherichia coli*, *K. pneumoniae*, *Ralstonia eutropha* (formerly *Alcaligenes eutrophus*), *Alcaligenes latus* or other microorganisms able to synthesize PHAs, or a higher plant or plant component, such as the seed of an oil crop (Brassica, sunflower, soybean, corn, safflower, flax, palm or coconut or starch accumulating plants (potato, tapioca, cassava). A screening procedure for the identification of genes encoding enzymes capable of converting 4-hydroxybutyric acid to 4-hydroxybutyryl-CoA and methods for redirecting the flux of normal cellular metabolites such as e.g. succinic acid and/or glutamic acid to 4-hydroxybutyric acid has been developed. The gene encoding a 4-hydroxybutyryl CoA transferase gene from the Gram-positive, strict anaerobic bacterium *Clostridium kluyveri* has been identified and used to express this enzyme activity in a transgenic organism to convert 4-hydroxybutyric acid into 4-

hydroxybutyryl-CoA resulting in the accumulation of poly(4-hydroxybutyrate) in *E. coli*. A bacteria expressing a functional PHA synthase from a transgene is described, as well as methods for expressing these genes in transgenic plant crops.

5           Screening systems for new 4-hydroxybutyryl CoA transferase encoding genes are also described. Transgenic *E. coli* strains in which a PHA synthase encoding gene is integrated in the chromosome and expressed to levels supporting PHA synthesis have been developed. With these transgenic strains can be screened with genomic libraries from  
10 different biological sources for activities that convert alternative PHA precursors such as 4-hydroxybutyrate to corresponding substrates for PHA synthase.

Techniques and procedures are provided to engineer new pathways in biological systems for the endogenous synthesis of alternative PHA  
15 monomers. Metabolism of any PHA production organism, including bacteria and plant crops, can be redirected to supply specific metabolites for PHA synthesis by metabolic engineering. In order to make this approach effective, it is necessary to develop new biochemical pathways leading to the desired monomer from one of the common metabolic  
20 intermediates. It is not necessary that such pathways exist in one organism since the individual steps can be reconstituted in the production organism of choice using genetic engineering techniques.

Incorporation of alternative monomers derived from supplemented feedstocks has specific drawbacks. First, additional feeds into a  
25 fermenter are costly as they expand the infrastructure and impose additional quality control. Second, addition of monomer precursors needs to be tightly controlled to achieve a constant composition of the monomer pools and PHA composition. Methods to engineer *E. coli* such as P(4HB) or PHB-co-4HB synthesis occurs from inexpensive carbohydrate  
30 feedstocks such as glucose, sucrose, xylose and lactose as the only carbon source. Enzyme activities in the  $\gamma$ -hydroxybutyrate shunt are elevated, while enzyme activities that drain intermediates from this shunt are

reduced. An alternative pathway yields 4HB from succinate. A similar approach in metabolic engineering can accommodate production of 4HB containing PHAs in organisms such as *A. eutrophus*, *A. latus* and *Comamonas* which are currently capable of producing 4-hydroxybutyrate copolymers from cosubstrates and in transgenic microbial and plant crop systems expressing a PHA synthesis from a heterologous PHA synthase gene or genes.

It is crucial for efficient PHA synthesis in recombinant *E. coli* strains that the expression of all the genes involved in the pathway be adequate. To this end, the genes of interest can be expressed from extrachromosomal DNA molecules such as plasmids, which intrinsically results in a copy number effect and consequently high expression levels, or, more preferably, they can be expressed from the chromosome. For large scale fermentations of commodity type products it is generally known that plasmid-based systems are unsatisfactory due to the extra burden of maintaining the plasmids and the problems of stable expression. These drawbacks can be overcome using chromosomally encoded enzymes by improving the transcriptional and translational signals preceding the gene of interest such that expression is sufficient and stable.

#### **Production of 4HB Copolymers**

Gerngross and Martin reported that substrates of PHA synthase require the presence of a coenzyme A (CoA) moiety (Gerngross, T.U. and Martin, D.P. (1955) Proc. Natl. Acad. Sci. USA 92:6279). The precursor required for the incorporation of 4HB is therefore 4HB-CoA. To determine the minimal requirement for the synthesis of 4-hydroxybutyrate containing PHAs, a mixture of 4-hydroxybutyrate, 3-hydroxybutyrate, 4-hydroxybutyrate CoA transferase purified from *Clostridium acetobutylicum* (Willadsen and Buckel, FEMS Microbiol. Lett. (1990) 70: 187-192) and PHB synthase (as purified by Gerngross et al. (1994) Biochemistry 33: 9311) was incubated *in vitro* under conditions as described by Gerngross and Martin (Gerngross, T.U. and Martin, D.P. (1995) Proc. Natl. Acad. Sci. USA 92:6279). The product of the reaction

was isolated and the incorporation of 4-hydroxybutyrate was confirmed by <sup>1</sup>H-NMR.

Having established the minimal requirements for the synthesis of 4-hydroxybutyrate containing PHA *in vitro*, it becomes evident that the minimal requirements for the synthesis of these PHAs *in vivo* includes a gene encoding 4-hydroxybutyrate CoA transferase or similar activity and 4-hydroxybutyrate. The substrate 4-hydroxybutyrate can be administered to the PHA producing microorganism or be synthesized *in vivo* by engineered biosynthetic pathways from appropriate substrates. Amino acid sequence was determined for the purified 4-hydroxybutyrate CoA transferase (Scherf and Buckel, Appl. Environ. Microbiol. (1991) 57:2699-2701). The purified protein was subjected to enzymatic digestion followed by amino acid sequence analysis of three of the resulting peptides. The amino acid sequence of these peptides and the N-terminus of the intact protein showed a striking homology to the OrfZ gene product (Figures 1A, 1B, 1C, and 1D), whose identity and function was not known, thereby identifying *orfZ* as the gene encoding 4-hydroxybutyryl CoA transferase in *C. kluyveri*. This gene was renamed *hbcT*.

Confirmation that introduction of this gene into an *E. coli* strain that expresses PHB synthase is sufficient for 4-hydroxybutyrate containing PHA synthesis was obtained as follows. The PHB synthase from *Z. ramigera* is expressed from a chromosomally integrated copy of this gene in *E. coli* strain MBX379. PHA was formed within the cells upon introduction of a plasmid encoding *hbcT* and supplying 4-hydroxybutyrate in the growth medium. In the absence of genes providing other enzymes of the PHB pathway, the accumulated PHA is P4HB. *E. coli* strain MBX777 contains the genes encoding  $\beta$ -ketothiolase, acetoacetyl CoA reductase and PHB synthase from *Z. ramigera*. Upon introduction of a plasmid encoding *hbcT* and supplying 4-hydroxybutyrate in the growth medium, a PHB-4HB copolymer was formed.

Further development of a PHB-4HB producing system is achieved by engineering the metabolic pathways of the transgenic organism such

that 4-hydroxybutyrate is synthesized from endogenous intermediates instead of being supplied externally. Two biochemical routes to the precursor 4HB-CoA can be established in a production organism for 4HB-containing PHAs. The first pathway proceeds from  $\alpha$ -ketoglutarate, the second from succinate. Substrate for both pathways can also be provided through amino acid degradation.

*Pathway to 4-hydroxybutyryl CoA from  $\alpha$ -ketoglutarate*

A pathway that enables the conversion of  $\alpha$ -ketoglutarate to 4-hydroxybutyryl CoA is shown in Figure 2. Enzymes involved in this pathway are  $\alpha$ -ketoglutarate transaminase, glutamate dehydrogenase, glutamate decarboxylase, 4-hydroxybutyrate dehydrogenase and 4-hydroxybutyrate CoA transferase.

Genes encoding these activities can be acquired from multiple sources:

*gdhA* gene encoding glutamate dehydrogenase: *E. coli* (Valle et al. Gene (1984) 27: 193-199 and Valle et al., Gene (1983) 23: 199-209), *Klebsiella aerogenes* (Mountain et al., Mol. Gen. Genet. (1985) 199:141-145), *Pyrococcus furiosus* (DiRuggiero et al., Appl. Environ. Microbiol. (1995) 61: 159-164; Eggen et al., Gene (1993) 132:143-148), *Sulfolobus shibatae* (Benachenhau et al. (1994), Gene 140: 17-24), *Rumonococcus flavefaciens* (Duncan et al., Appl. Environ. Microbiol. (1992) 58: 4032-4037), *Pseudomonas fluorescens* (Miyamoto et al., J. Biochem. (1992) 112:52-56), *Clostridium symbiosum* (Teller et al., Eur. J. Biochem. (1992) 206: 151-159), *Synechocystis* (Plant Mol. Biol. (1995) 28: 173-188), *Corynebacterium glutamicum* (Bormann et al., Mol. Microbiol. (1992) 6:301-308), *Peptostreptococcus asaccharolyticus* (Snedecor et al. (1991) J. Bacteriol. 173: 6162-6167), *Salmonella typhimurium* (Miller et al. (1984) J. Bacteriol. 157: 171-178), *Chlorella sorokiniana* (Cock et al., Plant Mol. Biol. (1991) 17: 1023-144), *Saccharomyces cerevisiae* (Nagasu et al., Gene (1984) 37:247-253), *Neurospora crassa* (Kinnaird et al., Gene (1983) 26:253-260), *Giardia lamblia* (Yee et al (1992) J. Biol. Chem. 267: 7539-7544).

- gadA* and/or *gadB* encoding glutamate-succinic semialdehyde transaminase: *E. coli* (Metzer and Halpern, J. Bacteriol. (1990) 172: 3250-3256 and Bartsch et al. J. Bacteriol. (1990) 172: 7035-7042) or *S. cerevisiae* (André and Jauniaux, Nucl. Acid Res. (1990) 18: 3049).
- 5        *4hbD* gene encoding the 4-hydroxybutyrate dehydrogenase: *C. kluyveri* (Söhling and Gottschalk, 1996, J. Bacteriol. 178, 871-880).
- 4-hydroxybutyryl CoA transferase gene: *C. aminobutyricum* (Willadsen and Buckel, FEMS Microbiol. Lett. (1990) 70: 187-192) or: *C. kluyveri* (Söhling and Gottschalk, 1996, J. Bacteriol. 178, 871-880).
- 10        Other sources of these genes in addition to the listed microorganisms which are of mammalian or plant origin:
- Glutamate dehydrogenase: (Syntichaki et al. (1996) Gene 168: 87-92), maize (Sakakibara et al. (1995), Plant Cell Physiol. 36: 789-797), human (Tzimagiogis et al. (1993), Hum. Genet. 91: 433-438), mouse
- 15        (Tzimagiogis et al. (1991), Biochem. Biophys. Acta 1089: 250-253), Amuro et al. (1990), Biochem. Biophys. Acta 1049: 216-218).
- $\alpha$ -ketoglutarate transaminase: (Park et al. (1993), J. Biol. Chem. 268: 7636-7639), Kwon et al. (1992), J. Biol. Chem. 267: 7215-7216), rat (Thakur et al. (1988), Biochem. Int. 16:235-243), rabbit (Kirby et al.
- 20        (1985), Biochem. J. 230: 481-488).
- glutamate decarboxylase: tomato (Gallego et al. (1995), Plant Mol. Biol. 27: 1143-1151), human (Bu et al. (1994), Genomics 21:222-228), cat (Chu et al. (1994), Arch. Biochem. Biophys. 313: 287-295), plant (Baum et al. (1993), J. Biol. Chem. 268: 19610-19617).
- 25        Regulation of glutamate dehydrogenase expression has been studied primarily in *E. coli*. The corresponding *gdhA* gene is highly expressed in glucose/ammonia minimal medium and moderately catabolite repressed. Excess glutamate is degraded by aspartate aminotransferase (encoded by *aspC*). Two REP sequences downstream of the glutamate dehydrogenase
- 30        gene are involved in mRNA stabilization. The *P. fluorescens* glutamate dehydrogenase gene shows similar regulation by glucose. Glutamate

dehydrogenase from both *P. furiosus* and *C. glutamicum* is expressed in *E. coli* because they complement a *gdhA* mutation.

The *gab* gene cluster is only expressed at low constitutive levels due to catabolite repression by glucose and ammonia. When a poor  
5 nitrogen source or succinate as carbon source are supplied the operon is derepressed. Thus, both cAMP/CRP and NtrC regulate the promoter, in addition to a specific repressor encoded by *gabC*. The promoter that regulates *gabT* is located upstream of *gabD*. Succinate semialdehyde dehydrogenases are encoded by *gabD* and *sad*. These activities could be  
10 deleterious for the purpose of P4HB or PHB-4HB production although their expression is expected to be repressed by the presence of sufficient glucose and nitrogen sources. Glutamate decarboxylase is a rare enzyme among the Enterobacteriaceae. It is pyridoxal phosphate dependent and well expressed at low pH.

15 *Pathways to 4-hydroxybutyryl-CoA from arginine, putrescine, glutamine and proline via GABA*

Bacteria such as *Escherichia coli* are capable of catabolizing at least four different amino acids (arginine, proline, glutamine, and glutamate) to produce GABA, which can be converted as described above  
20 to 4-hydroxy-butyryl-CoA. These catabolic pathways are depicted in Figure 3.

*E. coli* contains at least two activities, encoded by *speA* and *adi*, that can decarboxylate arginine to agmatine. Putrescine and urea are formed from agmatine by the action of agmatine ureohydrolase, encoded  
25 by *speB*. Putrescine donates an amino group to  $\alpha$ -ketoglutarate to form 4-aminobutyraldehyde and glutamate in a reaction catalyzed by the product of the *pat* gene, putrescine aminotransferase. The 4-aminobutyraldehyde is oxidized to GABA by aminobutyraldehyde dehydrogenase, encoded by *prf*. The synthesis of agmatine ureohydrolase, putrescine  
30 aminotransferase, and aminobutyraldehyde dehydrogenase is dually controlled by catabolite repression and nitrogen availability. Catabolite repression of agmatine ureohydrolase, but not that of putrescine

aminotransferase or aminobutyraldehyde dehydrogenase, can be relieved by cAMP. Agmatine ureohydrolase synthesis is induced by arginine and agmatine. Arginine decarboxylase synthesis is not sensitive to catabolite repression or to stimulation by nitrogen limitation or subject to substrate induction (Shaibe et al., J. Bacteriol. 163:938, 1995). There is a second arginine decarboxylase in *E. coli* which appears to be specialized for catabolism rather than biosynthesis of arginine, and this protein is encoded by the *adi* gene (Stim and Bennett, J. Bacteriol. 175:1221, 1993). It is induced under conditions of acidic pH, anaerobiosis, and rich medium.

Proline is degraded in *E. coli* by the product of the *putA* gene, which catalyzes successive oxidations of proline to pyrroline 5-carboxylate and then to glutamate. The first step is FAD-dependent, and thus the PutA protein is membrane-associated. This same protein also acts as a repressor of the *put* operon in the absence of proline. The *put* operon is subject to catabolite repression (McFall and Newman, pp. 358-379, in Neidhardt, ed., *Escherichia coli* and *Salmonella typhimurium*: cellular and molecular biology, ASM Press, Washington, D.C., 1996).

Glutamine is converted to glutamate in *E. coli* by glutamate synthase, the product of the *gltB* and *gltD* genes. Two molecules of glutamate are formed by the donation of an amino group by glutamine to  $\alpha$ -ketoglutarate. The activity of *E. coli* glutamate synthase is high when this organism is grown in ammonia-containing minimal medium and low when it is grown in the presence of glutamate or glutamate-generating nitrogen sources if nitrogen is limiting (Reitzer, pp. 391-407, in Neidhardt, ed., *Escherichia coli* and *Salmonella typhimurium*: cellular and molecular biology, ASM Press, Washington, D.C., 1996).

These pathways can be realized for the production of poly(4-hydroxybutyrate) in an organism such as *E. coli* by relying upon the organism's own genes or by importing such genes from another source into the organism of interest. These genes can be acquired from many organisms, such as:

*speA* encoding arginine decarboxylase: *Escherichia coli* (Moore and Boyle, J. Bacteriol. 172:4631, 1990), *Synechocystis* sp. (Kaneko et al., DNA Res. 3:109, 1996), *Helicobacter pylori* (Tomb et al., Nature 388:539, 1997), thale cress (*Arabidopsis thaliana*) (Watson et al., Plant Physiol. 114:1569, 1997), soybean (*Glycine max*) (Nam et al., Plant Cell Physiol. 38:1156, 1997), clove pink (*Dianthus caryophyllus*) (Chang et al., Plant Physiol. 112:863, 1996), pea (*Pisum sativum*) (Perez-Amador et al., Plant Mol. Biol. 28:997, 1995), tomato (*Lycopersicon esculentum*) (Rastogi et al., Plant Physiol. 103:829, 1993), oat (*Avena sativa*) (Bell and Malmberg, Mol. Gen. Genet. 224:431, 1990), plants of the family Brassicaceae (*Barbarea vulgaris*, *Nasturtium officinale*, *Arabis drummondii*, *Aethionema grandiflora*, *Capsella bursa-pastoris*, *Arabidopsis arenosa*, *Sisymbrium altissimum*, *Thellungiella salsuginea*, *Polanisia dodecandra*, *Stanleya pinnata*, *Carica papaya*, *Brassica oleracea*, *Brassica nigra*, *Theobroma cacao*) (Galloway et al., Mol. Biol. Evol. 15, 1998), rat (Morrissey et al., Kidney Int. 47:1458, 1995).

*adi* encoding biodegradative arginine decarboxylase: *Escherichia coli* (Stim and Bennett, J. Bacteriol. 175:1221, 1993).

*speB* encoding agmatine ureohydrolase: *Escherichia coli* (Szumanski and Boyle, J. Bacteriol. 172:538, 1990), *Streptomyces clavuligerus* (Aidoo et al., Gene 147:41, 1994), *Bacillus subtilis* (Presecan et al., Microbiology 143:3313, 1997), *Synechocystis* sp. (Kaneko et al., DNA Res. 3:109, 1996), *Methanobacterium thermoautotrophicum* (Smith et al., J. Bacteriol. 179:7135, 1997), *Archaeoglobus fulgidus* (Klenk et al., Nature 390:364, 1997).

*pat* encoding putrescine aminotransferase and *prp* encoding aminobutyraldehyde dehydrogenase: *Escherichia coli* (Shaibe et al., J. Bacteriol. 163:938, 1985).

*gltBD* encoding glutamate synthase: *Escherichia coli* (Oliver et al., Gene 60:1, 1987), *Aquifex aeolicus* (Deckert et al., Nature 392:353, 1998), *Azospirillum brasilense* (Pelanda et al., J. Biol. Chem. 268:3099, 1993), alfalfa (*Medicago sativa*) (Gregerson et al., Plant Cell 5:215,

- 1993), baker's yeast (*Saccharomyces cerevisiae*) (Filetici et al., Yeast 12:1359, 1996; Cogoni et al., J. Bacteriol. 177:792, 1995),  
*Methanococcus jannaschii* (Bult et al., Science 273:1058, 1996),  
*Methanobacterium thermoautotrophicum* (Smith et al., J. Bacteriol.  
5 179:7135, 1997), *Bacillus subtilis* (Petit et al., Mol. Microbiol. 29:261, 1998), *Azospirillum brasilense* (Mandal and Ghosh, J. Bacteriol. 175:8024, 1993).

- putA* encoding pyrroline-5-carboxylate reductase: *Streptomyces coelicolor* (Redenbach et al., Mol. Microbiol. 21:77, 1996),  
10 *Mycobacterium tuberculosis* (Cole et al., Nature 393:537, 1998), *Haemophilus influenzae* (Fleischmann et al., Science 269:496, 1995), *Escherichia coli* (Blattner et al., Science 277:1453, 1997), baker's yeast (*Saccharomyces cerevisiae*) (Science 265:2077, 1994), *Vibrio alginolyticus* (Nakamura et al., Biochim. Biophys. Acta 1277:201, 1996),  
15 *Pseudomonas aeruginosa* (Savoiz et al., Gene 86:107, 1990), *Klebsiella pneumoniae* (Chen and Maloy, J. Bacteriol. 173:783, 1991), *Salmonella typhimurium* (Allen et al., Nucleic Acids Res. 21:1676, 1993), *Agrobacterium tumefaciens* (Cho et al., J. Bacteriol. 178:1872, 1996), *Sinorhizobium meliloti* (Jimenez-Zurdo et al., Mol. Microbiol. 23:85,  
20 1997), *Rhodobacter capsulatus* (Keuntje et al., J. Bacteriol. 177:6432, 1995), *Bradyrhizobium japonicum* (Straub et al., Appl. Environ. Microbiol. 62:221, 1996), *Synechocystis* sp. (Kaneko et al., DNA Res. 3:109, 1996), *Shewanella* sp. (Kato et al., J. Biochem. 120:301, 1996), *Photobacterium leiognathi* (Lin et al., Biochem. Biophys. Res. Commun.  
25 219:868, 1996), *Helicobacter pylori* (Tomb et al., Nature 388:539, 1997), cultivated mushroom (*Agaricus bisporus*) (Schaap et al., Appl. Environ. Microbiol. 63:57, 1997), soybean (*Glycine max*) (Delauney and Verma, Mol. Gen. Genet. 221:299, 1990), human (*Homo sapiens*) (Campbell et al., Hum. Genet. 101:69, 1997).  
30 The arginine, proline, glutamine, or glutamate can be supplied exogenously to the poly(4-hydroxybutyrate)-producing organism, or it can be synthesized in the host from another carbon source, preferably an

inexpensive one such as glucose. *E. coli*, for example, synthesizes all of these compounds from glucose, but generally only to an extent sufficient for growth.

Strains of *E. coli* that overproduce these compounds have been developed. Tujimoto et al. (U.S. Patent 5,378,616) describe an *E. coli* mutant that accumulates glutamate. Momose et al. (U.S. Patent 4,430,430) describe the overexpression of the *argA* gene in *E. coli*, which leads to arginine accumulation. Proline-resistant mutants of *E. coli* that overexpress proline synthesis genes can accumulate proline (Wang et al., Chin. J. Biotechnol. 6:27, 1990). Tobacco plants which overexpress bacterial proline synthesis genes were also shown to accumulate proline (Sokhansandzh et al., Genetika 33:906, 1997). Furthermore, *E. coli* and other bacteria accumulate glutamate, GABA, and proline as a response to high medium osmolarity (McLaggan et al., J. Biol. Chem. 269:1911, 1994; Measures, J.C., Nature 257:398, 1975; Schleyer et al., Arch. Microbiol. 160:424, 1993; Botsford et al., Appl. Environ. Microbiol. 60:2568, 1994).

*Pathway to 4-hydroxybutyryl CoA from succinate*

The complete biochemical pathway for the conversion of succinate to 4HB-CoA (Figure 4) has been characterized in *Clostridium kluyveri* (Söhling and Gottschalk, 1993, Eur. J. Biochem. 212, 121-127; Wolff et al., 1993, Appl. Environ. Microbiol. 59, 1876-1882; Scherf et al., 1994, Arch. Microbiol. 161, 239-245). More recently, the genes encoding the *C. kluyveri* succinyl-CoA: CoA transferase (*catI*), succinate-semialdehyde dehydrogenase (*sucD*) and 4-hydroxybutyrate dehydrogenase (*4hbD*) have been identified (Söhling and Gottschalk, 1996, J. Bacteriol. 178, 871-880). These genes are located in a contiguous stretch of DNA on the *C. kluyveri* chromosome and flanked by three genes of unknown function (*orfZ*, *orfY* and *sigL*). The genes appear to be induced by succinate in the growth medium. The gene encoding 4-hydroxybutyryl CoA transferase was not identified in these studies.

*Identification of alternative genes encoding enzymes that operate in the synthesis of 4-hydroxybutyrate*

Alternative genes encoding enzymes that operate in the conversion of either  $\alpha$ -ketoglutarate or succinate to 4HB can be isolated by  
5 complementation or expression studies: glutamate-succinic semialdehyde transaminase genes can be isolated from gene libraries because of the ability of this gene to complement an *E. coli gabT* mutation for utilization of  $\gamma$ -aminobutyric acid as nitrogen source. Likewise, mutations in glutamate dehydrogenase and glutamate decarboxylase genes in *E. coli*  
10 can be complemented. Expression of alternative 4-hydroxybutyrate dehydrogenase genes will allow *E. coli* to utilize 4-hydroxybutyrate as a carbon source. Enzyme homology searches using the BLASTP program and the GenBank database suggest the presence of 4-hydroxybutyrate dehydrogenase homologs in the *E. coli* genome. These proteins have  
15 been identified with the genetic index numbers: gi | 1788795 and gi | 1790015.

*Importance of Integration; Screening for Polymer Production*

It is important for efficient PHA production that strains do not lose the capability to synthesize the biopolymer for the duration of the  
20 inoculum train and the production run. Loss of any of the *phb* genes results in loss of product whereas loss of any of the genes that provide new monomers results in heterogeneous product formation. Both are undesirable and stable propagation of the strain is therefore required. Unfortunately, merely integrating the gene encoding the transferase or  
25 synthase does not result in significant polymer production. It is necessary to enhance enzyme expression, through alteration of the promoter region or mutagenesis or other known techniques, followed by screening for polymer production. Using these techniques, integration of the genes in the strains described in the examples was determined to be stable for at  
30 least 50 generations, sufficient for production in 100,000 L vessels.

Growth and morphology of these recombinant PHA producers is not compromised by the presence of *phb* genes on the chromosome.

During the selection procedures, individual integrants are selected on minimal medium plates circumventing the isolation of auxotrophic strains. Growth rates of the different *phb* integrants were similar to that of the wild-type *E. coli* strains from which the PHB producers were derived.

- 5 The addition of the *phb* genes to the *E. coli* chromosome did not affect the downstream processing of these strains, as they were still easily lysed by conventional methods.

The present invention will be further understood by reference to the following non-limiting examples.

10 **Example 1: Minimal requirements for PHB-4HB synthesis**

- It has been previously shown that the minimum requirements for the synthesis of poly-(*R*-3-hydroxybutyrate) (PHB) are the purified PHA synthase from *A. eutrophus* and the substrate (*R*)-3-hydroxybutyryl-CoA. 4-Hydroxybutyryl-CoA can be prepared *in situ* from acetyl-CoA and 4-  
15 hydroxybutyrate via a transthiioesterification reaction catalyzed by the enzyme 4-hydroxybutyryl-CoA transferase, isolated from *Clostridium aminobutyricum*. This enzyme will also catalyze the formation of (*R*)-3-hydroxybutyryl-CoA from the free acid and acetyl-CoA. Thus the minimum requirements for the *in situ* synthesis of 4-hydroxybutyryl-CoA  
20 and its co-polymerization with (*R*)-3-hydroxybutyryl-CoA to form P(3HB-co-4HB) would include PHA synthase, (*R*)-3-hydroxybutyric acid, 4-hydroxybutyric acid, acetyl-CoA and 4-hydroxybutyryl-CoA transferase in a buffered aqueous solution. This was demonstrated as follows:

- 25 To potassium phosphate buffer (1 ml, 100 mM, pH 7.5) the following were added:

- acetyl-CoA (0.5 mL, 30 mM)  
4-hydroxybutyric acid sodium salt (50  $\mu$ l, 2 M)  
(*R*)-3-hydroxybutyric acid sodium salt (100  $\mu$ l, 1 M)  
4-hydroxybutyryl-CoA transferase (10 mg, 25 units)  
30 PHA synthase (0.05 mg)

The reaction was allowed to stand at room temperature overnight. The formation of insoluble PHA granules was noted. Insoluble material was

pelleted by centrifugation and freeze dried (0.65 mg). This material had a sticky consistency. Organic material was extracted with  $\text{CDCl}_3$  and analyzed by  $^1\text{H-NMR}$ . NMR analysis confirmed the formation of poly-((R)-3-hydroxybutyrate-co-4-hydroxybutyrate) containing approximately 20% 4-hydroxybutyric acid. The NMR spectrum matches a literature spectrum of poly-((R)-3-hydroxybutyrate-co-4-hydroxybutyrate) (Doi, Y. et al., *Macromolecules* 1988, 21: 2722-2727).

**Example 2:** *Poly(4-hydroxybutyrate) (P4HB) synthesis in E. coli using a plasmid encoded pathway*

The *hbcT* gene from *C. kluyveri* was expressed in *E. coli* using standard molecular biological techniques. The gene is placed in an appropriate vector behind a strong promoter and under conditions that drive expression from this promoter. 4HBCT is produced.

Strains of *E. coli* were equipped with plasmid pFS30 which contains the genes encoding 4-hydroxybutyryl-CoA transferase from *C. kluyveri* and PHB synthase from *R. eutropha*. These genes are expected to convert 4-hydroxybutyric acid into 4-hydroxybutyryl-CoA which is subsequently polymerized to poly(4-hydroxybutyrate). Strains were grown in 250 ml Erlenmeyer flasks containing 50 to 100 ml 10% LB liquid medium with 4-hydroxybutyrate, alone or in combination with glucose, as carbon source. Cultures were incubated at 30 to 33 °C with shaking at 150 or 200 rpm. Cultures were harvested after 24 hours of incubation and analyzed for PHA. *E. coli* MBX1177 (a spontaneous mutant of strain DH5 $\alpha$  selected for growth on minimal 4-HB medium) with pFS30 accumulates 67% of its cell dry weight as a P4HB homopolymer:

	host	volume	rpm	4HB	glc	T	%LB	%PHA	F(4HB)
	19	50 ml	150	5	2	33	10	<5	1.0
	184	100 ml	150	5	2	33	10	38.9	1.0
	816	100 ml	200	5	0	32	10	19.3	>0.99
5	817	100 ml	200	5	0	32	10	12.8	>0.99
	821	100 ml	200	5	0	32	10	24.8	>0.99
	1177	50 ml	150	5	0	33	10	14.8	1.0
	1177	100 ml	200	5	2	30	10	67.1	1.0

**Example 3:** *Poly(4-hydroxybutyrate) (P4HB) synthesis in E. coli using a plasmid encoded PHA synthase.*

Strains of *E. coli* were equipped with plasmid pFS16, which contains the gene encoding 4-hydroxybutyryl-CoA transferase from *C. kluyveri*. This gene is expected to convert 4-hydroxybutyric acid into 4-hydroxybutyryl-CoA which is subsequently polymerized by a chromosomally encoded PHB synthase into P4HB. Strains were grown in 250 ml Erlenmeyer flasks containing 50 to 100 ml 10% LB or 100% LB liquid medium with 4-hydroxybutyrate, alone or in combination with glucose, as carbon source. Cultures were incubated at 32 to 37 °C with shaking at 0 to 250 rpm. Cultures were harvested after 24 hours of incubation and analyzed for PHA. *E. coli* MBX769 with pFS16 accumulates 67% of its cell dry weight as a P4HB homopolymer. Formation of 4HB containing PHAs is consequently not dependent on a plasmid encoded PHB synthase.

	host	volume	rpm	4HB	glc	T	%LB	%PHA	F(4HB)
25	777	50 ml	250	5	0	37	100	7.6	0.36
	769	50 ml	250	5	0	37	100	0	-
	769	50 ml	100	5	0	33	10	8.0	0.18
	769	100 ml	150	5	2	33	10	16.4	0.25
	769	100 ml	200	5	2	32	10	43.5	0.37
30	769	100 ml	0	5	0	33	10	13.6	0.29
	769	100 ml	0	5	0	33	10	19.8	0.32
	769	100 ml	250	5	0	37	10	2.4	0.002

**Example 4: Construction of plasmids for chromosomal integration of *phb* genes.**

Plasmid pMUXC<sub>5</sub>cat contains the *phbC* gene from *Z. ramigera* on a transposable element for integration of this gene on the chromosome of a recipient strain (Figure 5). Strong translational sequences were obtained from pKPS4 which encodes PHA synthase encoding *phaC1* from *P. oleovorans* in the pTrc vector (Pharmacia). In this construct, *phaC1* is preceded by a strong ribosome binding site: AGGAGGTTTT(-ATG). The *phaC1* gene, including the upstream sequences, was cloned as a blunt ended *EcoRI-HindIII* fragment in the *SmaI* site of pUC18Sfi to give pMSXC<sub>3</sub>. A blunt ended *cat* gene cassette was subsequently cloned in the blunt-ended *Sse8387II* site, resulting in pMSXC<sub>3</sub>cat. At this point, all of the *phaC1* coding region except the 5' 27 base pairs were removed as a *PstI-BamHI* fragment and replaced by the corresponding fragment from the *phbC* gene from *Z. ramigera*. The resulting plasmid, pMSXC<sub>5</sub>cat, encodes a hybrid PHB synthase enzyme with the 9 amino terminal residues derived from the *P. oleovorans* PHA synthase and the remainder from *Z. ramigera*. The C<sub>5</sub>cat cassette was then excised as an *AvrII* fragment and cloned in the corresponding sites of pUTHg, thereby deleting the mercury resistance marker from this vector. The resulting plasmid, pMUXC<sub>5</sub>cat, contains a C<sub>5</sub>cat mini-transposon in which *phbC* is not preceded by a promoter sequence. Expression of the cassette upon integration is therefore dependent on transcriptional sequences that are provided by the DNA adjacent to the integration site.

pMSXTp<sub>1</sub>AB<sub>5</sub>kan2 was constructed from pMSXTp<sub>1</sub>kan as follows (Figures 6 and 6A). First pMSXTp<sub>1</sub>kan was digested with *NdeI*, filled in with Klenow and religated to obtain pMSXTp<sub>1</sub>kan2 in which the *NdeI* site is deleted. This deletion results in a unique *NdeI* site just upstream of *phbA* of *Z. ramigera* during later stages of the cloning procedure.

B<sub>5</sub> was cloned as a *NarI* fragment from pZT1 and cloned in the *HincII* site of pUC18Sfi to generate pMSXB<sub>5</sub>. A<sub>5</sub> was inserted as an *FseI*/blunt-*Sall* fragment in the *Ecl136II-Sall* sites resulting in pMSXAB<sub>5</sub>.

and regenerating the *Z. ramigera* AB<sub>5</sub> intergenic region. pMSXAB<sub>5</sub>cat was created by inserting a promoterless *cat* cassette in the *HindIII* site of pMSXAB<sub>5</sub>. The AB<sub>5</sub> fragment from pMSXAB<sub>5</sub>cat was cloned as a *EcoRI*-*PstI* fragment into the *SmaI* site of pMSXTP<sub>1</sub>kan2 giving

5 pMSXTP<sub>1</sub>AB<sub>5</sub>kan2.

Expression of *phbAB5* was improved by introduction of a strong promoter upstream of these genes (Figures 6 and 6A). This promoter was generated with sets of oligonucleotides that provide upstream activating sequences, a -35 promoter region, a -10 promoter region with transcriptional

10 start site(s), and mRNA sequences with possible stabilizing functions. Plasmid pMSXTP<sub>1</sub>AB<sub>5</sub>kan2 was digested with *PstI*/*XbaI* and a fragment containing the -10 region of the *lac* promoter was inserted as a fragment obtained after annealing oligonucleo-tides

3A

15 (5'GGCTCGTATAATGTGTGGAGGGAGAACCGCCGGGCTCGCGCCGTT)  
and

3B (5' CTAGAACGGCGCGAGCCCGGCGGTTCTCCCTCCACA  
CATTATACGA GCCTGCA).

Next, a fragment containing a consensus *E. coli pho* box and -35 promoter region were inserted into the *PstI* site as a fragment obtained after annealing the oligonucleotides: 2A: (5' TCCCC TGTCATAAAGTTGTCACTGCA) and 2B (5' GTGACAACTTTATGACAGGGG ATGCA). Next, the messenger stabilizing sequence including the transcriptional start site from AB<sub>5</sub> was inserted into the *XbaI*-*NdeI* sites as a fragment obtained after

25 annealing the oligonucleotides: 4A (5': CTAGTGCCGG  
ACCCGGTTCCAAGGCCGGCCGCAAGGCTGCCAGAACTGAGGAAG  
CACA) and 4B:

(5'TATGTGCTTCCTCAGTTCTGGCAGCCTTGCGGCCGGCCTTGGA  
CCGGGTCCGGCA). The resulting plasmid is pMSXp<sub>12</sub>AB<sub>5</sub>kan2. The

30 *AvrII* fragment, containing TP<sub>12</sub>AB<sub>5</sub>kan2 was cloned into pUTHg cut with *AvrII* and used for integration into the genome of MBX379 and MBX245.

The p<sub>12</sub>AB<sub>5</sub>kan expression cassette were then excised as a 2.8 kb *AvrII* fragment and ligated into the *AvrII* site of pUTHg and transformed into *E. coli* strain CC118 λpir to obtain plasmids pMUXp<sub>12</sub>AB<sub>5</sub>kan. This plasmid was then transformed into *E. coli* S17-1λpir and used to insert

5 p<sub>12</sub>AB<sub>5</sub>kan expression cassettes into the chromosome of *E. coli* strains by conjugation (Herrero *et al.* J. Bacteriol. 1990, 172: 6557-6567).

**Example 5:** *Integration of phb genes into the chromosome of E. coli.*

Material and Methods

*E. coli* strains were grown in Luria-Bertani medium (Sambrook *et al.*, Molecular Cloning, a laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) at 37 °C or 30 °C or in minimal E2 medium (Lageveen *et al.*, Appl. Environ. Microbiol. 1988, 54: 2924-2932). DNA manipulations were performed on plasmid and chromosomal DNA purified with the Qiagen plasmid preparation or

15 Qiagen chromosomal DNA preparation kits according to manufacturers recommendations. DNA was digested using restriction enzymes (New England Biolabs, Beverly, MA) according to manufacturers recommendations. DNA fragments were isolated from 0.7% agarose-Tris/acetate/EDTA gels using a Qiagen kit.

20 Plasmid DNA was introduced into *E. coli* cells by transformation or electroporation (Sambrook *et al.* Molecular Cloning, a laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Transposition of *phb* genes from the pUT vectors was achieved by mating of the plasmid donor strain and the recipient (Herrero

25 *et al.* J. Bacteriol. (1990) 172: 6557). The recipient strains used were spontaneous naladixic acid or rifampicin resistant mutants of *E. coli* derived from either LS5218 or MBX23. MBX23 is LJ14 *rpoS*::Tn10 in which the *rpoS*::Tn10 allele was introduced by P1 transduction from strain 1106 (Eisenstark). Recipients in which *phb* genes have been

30 integrated into the chromosome were selected on naladixic acid or rifampicin plates supplemented with the antibiotic resistance specified by the mini-transposon, kanamycin or chloramphenicol. Oligonucleotides

were purchased from Biosynthesis or Genesys. DNA sequences were determined by automated sequencing using a Perkin-Elmer ABI 373A sequencing machine. DNA was amplified using the synthase-chain-reaction in 50 microliter volume using PCR-mix from Gibco-BRL

5 (Gaithersburg, Md) and an Ericomp DNA amplifying machine.

Accumulated PHA was determined by gas chromatographic (GC) analysis as follows. About 20 mg of lyophilized cell mass was subjected to simultaneous extraction and butanolysis at 110°C for 3 hours in 2 mL of a mixture containing (by volume) 90% 1-butanol and 10% concentrated  
10 hydrochloric acid, with 2 mg/mL benzoic acid added as an internal standard. The water-soluble components of the resulting mixture were removed by extraction with 3 mL water. The organic phase (1  $\mu$ L at a split ratio of 1:50 at an overall flow rate of 2 mL/min) was analyzed on an HP 5890 GC with FID detector (Hewlett-Packard Co, Palo Alto, CA)  
15 using an SPB-1 fused silica capillary GC column (30 m; 0.32 mm ID; 0.25  $\mu$ m film; Supelco; Bellefonte, Pa.) with the following temperature profile: 80 °C, 2 min; 10 C° per min to 250 °C; 250 °C, 2 min. The standard used to test for the presence of 4-hydroxybutyrate units in the polymer was  $\gamma$ -butyrolactone, which, like poly(4-hydroxybutyrate), forms  
20 n-butyl 4-hydroxybutyrate upon butanolysis. The standard used to test for 3-hydroxybutyrate units in the polymer was purified PHB.

1-Methyl-3-nitro-1-nitroso-guanidine (NTG) mutagenesis was performed as described by Miller (A short course in bacterial genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) using a  
25 90 minute treatment with 1 mg/ml NTG corresponding to 99% killing.

### Results

C<sub>3</sub>cat was introduced into the chromosome of MBX23 by conjugation using S17-1  $\lambda$ pir (pMUXC<sub>3</sub>cat) the donor strain. The conjugation mixture was spread on LB/Nl/Cm plates and integrants were  
30 obtained of which 40% were sensitive to ampicillin, indicating that no plasmid was present in these strains. Five integrants were transformed with pMSXAB<sub>3</sub>cat (Ap<sup>r</sup>) and grown on LB/Ap/Cm/2% glucose to examine

biosynthetic activity of PHB synthase. MBX326 expressed the highest synthase activity and was used in further studies. Expression of PHB synthase was increased by restreaking MBX326 successively on LB plates containing 100, 200, 500 and 1000  $\mu\text{g/ml}$  chloroamphenicol. Strain  
5 MBX379 is derived from MBX326 and exhibits chloramphenicol resistance up to 1000  $\mu\text{g/ml}$ .

*E. coli* S17-1  $\lambda\text{pir}$  containing  $\text{pMUX}_{\text{p}_{12}\text{AB}_5\text{kan}}$  was mated with MBX379. Transgenic strains in which *phbAB<sub>5</sub>kan* had integrated on the chromosome were selected on LB/Ni/Km plates. Among the integrants,  
10 PHB producers were identified on LB/glucose plates and MBX677 (MBX379::  $\text{p}_{12}\text{AB}_5\text{kan}$ ) was used for further studies. The PHB level in this strain grown in Luria-Bertani/2% glucose medium was 58% whereas 38% PHB was accumulated in minimal medium supplemented with 2% glucose.

15 **Example 6:** *Mutagenesis of transgenic E. coli strains for enhanced PHB production.*

Mutagenesis using NTG or EMS was used to improve PHB formation in MBX680. Strain MBX769 and MBX777 were selected after treatment of MBX680 with EMS and NTG respectively. These strains  
20 are able to grow on R2-medium supplied with 1% glucose, 0.5% corn steep liquor and 1 mg/ml chloroamphenicol. MBX769 was grown in 50 ml R-10 medium/ 0.5% CSL with 2 or 3% glucose at 37 °C for 20 to 26 hours. PHB was accumulated to 71% of the cell dry weight. Similarly, MBX769 was grown in 50 ml LB with or without 0.375 g/L  $\text{KH}_2\text{PO}_4$ ,  
25 0.875  $\text{K}_2\text{HPO}_4$  and 0.25  $(\text{NH}_4)_2\text{SO}_4$  and a total of 50 g/L glucose (five aliquots were added over the course of the incubation). After 63 hours of incubation, PHB had accumulated up to 96% of the cell dry weight. PHB levels in MBX777 strain grown in Luria-Bertani/2% glucose medium was 67% whereas in minimal medium supplemented with 2% glucose 57%  
30 PHB was accumulated.

Improved transgenic *E. coli* strains with a chromosomal *phbC* gene were obtained by P1 transduction of the C5cat allele from MBX379 into

LS5218, LS5218 *fadABI01::Tn10* and LS5218 *fadR<sup>+</sup> zcf117::Tn10*. The resulting strains are MBX816, MBX817 and MBX821, respectively.

**Example 7:** *Poly(4-hydroxybutyrate) (P4HB) synthesis in E. coli using an endogenous 4-hydroxybutyryl-CoA transferase activity.*

- 5           *E. coli* contains an endogenous gene encoding an enzyme with 4-hydroxybutyryl-CoA transferase activity. Strains MBX821 and 1231 were grown in 250 ml Erlenmeyer flasks containing 50 to 100 ml 10% LB liquid medium with 4-hydroxybutyrate, alone or in combination with glucose, as carbon source. MBX1231 is a mutant of MBX821 obtained
- 10 after treatment with 1-methyl-3-nitro-1-nitrosoguanidine and selected on plates containing 500 µg/ml chloramphenicol. Cultures were incubated at 32 to 33 °C with shaking at 200 rpm. Cultures were harvested after 24 hours of incubation and analyzed for PHA. Table x shows that these strains accumulate 2.5 to 3.5% of the cell dry weight as a P4HB
- 15 homopolymer. P4HB formation in this strain is not dependent on a plasmid encoded PHB synthase nor a heterologously expressed 4-hydroxybutyryl-CoA transferase. When these strains are grown on solid media, P4HB levels are improved to around 11%.

	host	volume	rpm	4HB	glc	T	%LB	%PHA	F(4HB)
20	821	100	200	5	2	32	10	2.5	1.0
	1231	100	200	5	2	33	10	3.5	1.0
	821	on plate		5	2	RT	10	10.5	1.0
	1231	on plate		5	2	RT	10	11.5	1.0

**Example 8:** *A screening method for air insensitive 4-hydroxybutyryl CoA transferase*

25

The 4-hydroxybutyryl-CoA transferase from *C. kluyveri* appears to be inhibited by air, most likely by oxygen. Oxygen insensitive mutants can be screened for by growing mutants of an *E. coli* strain that harbors

the 4-hydroxybutyryl-CoA transferase encoding *hbcT* gene on a plasmid and a PHA synthase gene on the chromosome, for P4HB synthesis under high oxygenation conditions and searching for white colonies (indicative of PHA accumulation) where the majority of the population forms grey colonies. Oxygen insensitive strains, MBX240 [pFS16], MBX379 [pFS16] and MBX830 [pFS16], were identified using this method.

Populations of mutants can be generated *in vivo* by treating the original strain with chemical mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine or ethylmethanesulfonate or with ultraviolet radiation.

Alternatively, an *hbcT* containing plasmid can be mutagenized *in vitro* with hydroxylamine. Mutants expressing a functional 4-hydroxybutyryl-CoA transferase are then screened for on solid media or highly oxygenated liquid media for P4HB formation from 4-hydroxybutyrate.

**Example 9:** *A screening method for additional E. coli genes encoding 4-hydroxybutyryl CoA biosynthetic enzymes*

Expression of the enzymatic activity that converts 4HB to 4HB-CoA in MBX821 or 1231 may be elevated by mutagenesis. Appearance of P4HB in MBX821 and 1231 grown on solid media took approximately 150 hours. Mutants with improved P4HB accumulation characteristics can be screened for after random mutagenesis of these strains with chemical mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine or ethylmethanesulfonate or with ultraviolet radiation. Desired mutants form white colonies within 2 to 5 days of incubation in the presence of 4-hydroxybutyrate.

**Example 10:** *A screening method for other genes encoding 4-hydroxybutyryl CoA biosynthetic enzymes*

Because applications involving plant systems require DNA with a high GC content, alternative 4-hydroxybutyryl CoA biosynthetic genes need to be identified and isolated. The low GC content of the *hbcT* gene would make it a useful probe for identification and isolation of homologous genes from other AT-rich DNA containing microorganisms. *HbcT* genes with a high GC content however will not be identified by this

method. *E. coli* strains that have a chromosomally integrated *phbC* gene encoding PHA synthase can be used to screen for such genes. For applications where genes are introduced into plants it is desirable to use DNA with a high GC content (Perlak F.J. *et al.*, Proc. Natl. Acad. Sci. USA (1991) 88: 3324). When *hbcT* genes are expressed in *E. coli* MBX379 for instance, this strain is able to produce a P4HB polymer on agar plates containing 4-hydroxybutyrate in addition to the common nutrients. The formation of P4HB gives the colony an easily distinguishable white phenotype. Thus, gene libraries of PHB-co-4HB producing organisms, such as *R. eutropha*, *A. latus*, *P. acidovorans*, *C. testosteroni* and others are introduced into MBX379 or similar strains and directly plated on 4HB containing growth medium. White colonies are selected and the composition of the accumulated PHA is determined. Gene libraries are readily constructed from organisms of choice by isolating genomic DNA and cloning a representative collection of DNA fragments in plasmid vectors. Representative libraries should have 5,000 to 100,000 individual colonies. Libraries are either made as a broad host range library in vectors such as pLAFR3 or as *E. coli* libraries in vectors such as pUC19, pBR322. Depending on the type of library and the method of introducing the library in the host of choice, the genomic DNA fragments are either large (17-30 kb) or relatively small (2-6 kb). Libraries are introduced into the screening strains by electroporation, transformation or conjugation, dependent on the host and the vector used.

In addition to alternative 4-hydroxybutyryl CoA transferases, acyl CoA synthetases able to utilize 4-hydroxybutyrate as a substrate will be isolated by this method. Examples of genes encoding enzymes with such general activities are *fadD*, involved in uptake of long-side chain fatty acids, *atoDA*, involved in uptake of acetoacetate and short side chain fatty acids, *catE*, involved in degradation of aromatics, *aceAB*, encoding succinyl CoA synthetase, *acsA* and *acsB* encoding acetyl CoA synthetases and homologs of such genes. Alternatively the substrate specificity of these enzymes may be expanded to include 4-hydroxybutyrate by

introducing plasmids with randomly mutagenized acyl CoA synthetase or transferase genes. Alternatively, the *ygfH* gene from *E. coli* which shares significant homology with the *hbcT* gene from *C. kluyveri* may be explored for 4-hydroxybutyryl CoA activity.

5 **Example 11: Endogenous synthesis of 4HB-CoA from  $\alpha$ -ketoglutarate**

$\alpha$ -Ketoglutarate is a cellular metabolite that can be converted to 4HB as shown in Figure 7. The pathway consists of a cyclic reaction catalyzed by the *gabT*, *gadA/gadB* and *gdhA* gene products. Formation of succinic acid semialdehyde from this cycle is favored once the product is  
10 further converted to 4HB-CoA by 4-HB dehydrogenase and 4HB-CoA transferase, and polymerized into a PHA by PHA synthase.

For this purpose the following plasmids were constructed in pMSXcat:

- |    |    |            |  |
|----|----|------------|--|
|    | 1. | pMSX-TD    | <i>hbcT</i> - <i>4hbD</i>                |
| 15 | 2. | pMSX-ABT   | <i>gdhA-gadB-gabT</i>                    |
|    | 3. | pMTX-DBTT  | <i>4hbD-gadB-gabT-hbcT</i>               |
|    | 4. | PMSX-ABTTD | <i>gdhA-gadA-gabT-hbcT</i> - <i>4hbD</i> |

1. *4hbD* was obtained from pCK3 by PCR using the primers:

4HBD-N: 5 'CTCTGAATTCAAGGAGGAAAAATATGAAGTTAT  
20 TAAAATTGGC (*EcoRI*)

4HBD-C: 5 'TTTCTCTGAGCTCGGGATATTTAATGATTGTAGG  
(*SacI*).

The PCR product was cloned into pCR2.1 (pMBX-D). *hbcT* was cloned as an *SspI* -*EcoRI* fragment from pCK3 and cloned in *EcoRV/EcoRI*  
25 digested pMBX-D to give pMBX-TD. The artificial *hbcT*-*4hbD* operon was excised from pMBX-TD as a *NotI*-*KpnI* fragment and ligated into these sites in pUC18Sfi or pMSX-TP1 (pMSX-TD and pMSX-TP<sub>1</sub>-TD respectively) (Figure 8). The TD or TP<sub>1</sub>-TD fragment was excised as a *AvrII* fragment and ligated into *AvrII* digested pUTkan (pMUX-TD and  
30 pMUX-TP<sub>1</sub>-TD). This plasmid allows random insertion of the TD/TP<sub>1</sub>-TD construct in the chromosome of *E. coli*. Expression of integrated TD

is driven by an endogenous promoter whereas expression of integrated TP<sub>1</sub>-TD is driven by P<sub>1</sub>. Recombinants in which the construct had integrated were selected for their ability to grow on 4-hydroxybutyrate as sole carbon source. No antibiotic resistance marker was required to select the desired insertions.

Other genes encoding enzymes that facilitate conversion of succinic semialdehyde to 4-hydroxybutyryl CoA can be isolated routinely by complementation. After introduction of *4hbD* homologs such genes confer on wild-type *E. coli* strains the ability to use 4HB as sole carbon source.

2. An operon consisting of *gdhA-gadA-gabT* was created in plasmid pUC18Sfi and inserted in the *E. coli* chromosome using the pUTkan vector. Recipients of the construct were isolated on E2/glycerol/ $\gamma$ -hydroxybutyrate /N1 plates. Because the recipient strain is unable to use  $\gamma$ -hydroxybutyrate as nitrogen source (due to a *gabT* mutation), only those strains that express the operon grow on this medium.

The *gdhA* gene was obtained from the *E. coli* chromosome using PCR and the following primers:

GH-Up: 5' AACGAATTCAATTCAGGAGGTTTTTATGGATCAGAC  
ATATTCTCTGGAGTC (*EcoRI*)

GH-Dn: 5' TTGGGAGCTCTACAGTAAGAAATGCCGTTGG (*SacI*).

The *gadB* gene was obtained from the *E. coli* chromosome using PCR and the following primers:

GB-Up: 5' TAAGAGCTCAATTCAGGAGGTTTTTATGGATAAGAA  
GCAAGTAACGGATTTAAGG (*SacI*)

GB-Dn: 5' TTCCCGGGTTATCAGGTATGCTTGAAGCTGTTCTGT  
TGGGC (*XmaI*).

The *gabT* gene was obtained from the *E. coli* chromosome using PCR and the following primers:

GT-Up: 5' TCCGGATCCAATTCAGGAGGTTTTTATGAACAGCAA  
TAAAGAGTTAATGCAG (*BamHI*)

GT-Dn: 5' GATTCTAGATAGGAGCGGCGCTACTGCTTCGCC  
(*XbaI*).

DNA sequence information used to design the above primers was from GenBank, accession numbers: K02499 (*gdhA*), M84025 and X71917  
5 (*gadB*), M88334 (*gabT*).

The three PCR products were digested with the indicated enzymes and sequentially cloned in the pUC18Sfi vector (pMSX-ABT) (Figure 9). The operon was excised as an *EcoRI-SalI* fragment and cloned in pMSXTP<sub>1</sub> (pMSX-TP<sub>1</sub>-ABT). Either the ABT or TP<sub>1</sub>-ABT insert was  
10 moved to pUTkan to allow insertion of the *gdhA-gadA-gabT* operon in the chromosome of a *gabT* mutant of *E. coli* MBX245. Successful insertions were selected on E2/glycerol/ $\gamma$ -hydroxybutyrate /NI plates.

Because *gabT* expression allows the use of  $\gamma$ -hydroxybutyrate as nitrogen source, genes that express this function can be easily selected for  
15 on minimal medium plates in which  $\gamma$ -hydroxybutyrate serves as the only nitrogen source. Expression of *gabT* at the end of the operon necessitates the transcription of the upstream genes for which no direct selection is available.

Glutamate dehydrogenase functions in this pathway as a source to  
20 provide glutamate in catalytic amounts. If sufficient glutamate is present, additional GdhA activity may not be required and incorporation of this gene in the described constructs is therefore optional.

3. The operons described under 1 and 2 were combined as follows: pMSX-TD was digested with *KpnI*, T4 polymerase treated and digested  
25 with *XhoI*; pMSX-ABT or pMSX-BT were digested with *HindIII*, Klenow treated and digested with *Sall*; the purified TD fragment was subsequently ligated into the prepared pMSX-ABT and pMSX-BT plasmids (Figure 9).

**Example 12:** *Endogenous synthesis of 4HBCoA from GABA precursors*

30 The common metabolite GABA is derived from glutamate and is normally metabolized via succinic semialdehyde to succinate in central metabolism. It may be desirable to improve the pathways to GABA to

achieve high levels of the intermediates for P4HB formation. Besides the direct conversion of  $\alpha$ -ketoglutarate to glutamate by glutamate dehydrogenase, this conversion is also part of many transamination reactions for instance with substrates such as glutamine and other amino acids, or putrescine. Recombinant and mutant organisms that overproduce arginine (the precursor of putrescine), glutamine or proline, consequently have increased levels of glutamate and GABA which can be shunted to 4HB-CoA with *gabT*, *4hbD* and *hbcT* as described above (Figure 10).

10 **Example 13: Endogenous synthesis of 4HB-CoA from succinate**

*HbcT* is not required for *E. coli* to grow on 4-hydroxybutyrate when *cat1*, *4hbD* and *sucD* are introduced (Söhling and Gottschalk, 1996, J. Bacteriol. 178, 871-880) possibly because the reverse action of SucD, 4HBD and Cat1 converts 4HB to succinate, a central metabolite in *E. coli*. In principle, these genes together allow the conversion of succinate to 4-HB. The pathway as depicted in Figure 4 can then be assembled from the *cat1*, *sucD*, *4hbD* and *hbcT* genes of *C. kluyveri*. Alternatively, these genes can be isolated from other *Clostridium* species such as *C. aminobutyricum*. Although *E. coli* does have a succinyl-CoA:CoA transferase itself (*sucCD*; Mat-Jan et al. Mol. Gen. Genet. (1989) 215: 276-280), it is desirable to introduce this gene from another source because this activity is not prominent in *E. coli* (Amarasingham and Davis, J. Biol. Chem. (1965) 240: 3664-3668). Alternatively, expression of the *E. coli* gene can be optimized for the current application.

An operon was constructed for integration in the *E. coli* chromosome consisting of *hbcT-cat1-sucD-4hbD*. Strains in which integration was successful are able to grown on 4HB if *4hbD* is expressed (Söhling and Gottschalk, 1996, J. Bacteriol. 178, 871-880). The construction of this operon proceeded as follows (Figure 11):

A *BamHI-PstI* fragment from pCK3 containing *orfY*, *cat1*, *sucD* and the 5' end of *4hbD* was ligated in the corresponding sites of pMSXcat

(pMSX-Y1D). The *4hbD* gene was completed by inserting the *PstI-SacI* fragment of pMSX-D in *PstI-SphI* digested pMSX-Y1D (pMSX-Y1DD). To achieve this, both fragments in this ligation were T4 polymerase treated after the *SphI* and *SacI* digestions to create blunt ends before an additional *PstI* digestion was started. *OrfY* in pMSX-Y1DD was replaced with *hbcT* by digesting pMSX-Y1DD with *BamHI* and *PacI*, followed by blunt ending the fragment with Klenow/T4 polymerase and dephosphorylation, and then ligation of the *SspI/EcoRI*, Klenow treated *hbcT* fragment into this vector (pMSX-T1DD). A fragment providing the regulatory sequences, terminator and promoter was inserted as a blunt ended fragment in the *SmaI* site of pMSX-T1DD. An integration plasmid for this operon was constructed by cloning the insert of pMSX-T1DD as an *SfiI* fragment into pUTkan.

**Example 14:** *Improved endogenous synthesis of 4HBCoA*

In order to prevent drainage of intermediates from these new pathways, it may be desirable to inactivate the genes encoding aspartate transaminase (*aspC*) and the NADP and NAD dependent succinic semialdehyde dehydrogenases (*sad* and *gabD*). Mutations in the individual genes were obtained from different sources: A strain containing the *aspC13I* mutation is obtained from the *E. coli* Genetic Stock Center as strain CGSC5799. The *aspC* gene maps to minute 21.1 and is therefore linked to the Tn10 (Tc) marker in CAG12094 (*zcc-282* at 22.25 minutes) or CAG18478 (*zbj-1230* at 20.00 minutes) and to the Tn10Km marker in CAG12130 (*zcb-3111* at minute 21.00). No mutations in the *gabD* gene are known and deletion of this activity can be achieved by cloning the gene by PCR, insertion of a genetic marker such as antibiotic resistance, integration using *recBC* strains or vectors constructed for this purpose such as pMAK705 and finally, bacteriophage P1 transduction to transfer the gene to the desired host.

**Example 15 :**     *Expression of A PHA synthase and 4-hydroxybutyryl-CoA transferase in Oilseed Crops.*

Methods for the identification of genes encoding enzymes capable of forming 4-hydroxybutyryl-CoA from 4-hydroxybutyric acid (i.e.,  
5     having 4-hydroxybutyryl-CoA transferase activity) which can be expressed in a transgenic plant comprising a PHA synthase transgene were developed by standard procedures. In certain cases, it may also be useful to express other PHA biosynthetic genes such as a  $\beta$ -ketothiolase and/or acetoacetyl-CoA reductase in the plant crop of interest. Methods for  
10    expressing a PHA synthase transgene in an oilseed crop have been described (U.S. 5,245,023 and U.S. 5,250,430; U.S. 5,502,273; U.S. 5,534,432; U.S. 5,602,321; U.S. 5,610,041; U.S. 5,650,555; U.S. 5,663,063; WO, 9100917, WO 9219747, WO 9302187, WO 9302194 and WO 9412014, Poirier et.al., 1992 *Science* 256; 520-523, Williams  
15    and Peoples, 1996 *Chemtech* 26, 38-44) all of which are incorporated herein by reference. In order to achieve this goal, it is necessary to transfer a gene, or genes in the case of a PHA synthase with more than one subunit, encoding a PHA synthase from a microorganism into plant cells and obtain the appropriate level of production of the PHA synthase  
20    enzyme. In addition it may be necessary to provide additional PHA biosynthetic genes, eg. an acetoacetyl-CoA reductase gene, a 4-hydroxybutyryl-CoA transferase gene or other genes encoding enzymes required to synthesize the substrates for the PHA synthase enzymes. In many cases, it is desirable to control the expression in different plant  
25    tissues or organelles using methods known to those skilled in the art (Gasser and Fraley, 1989, *Science* 244; 1293-1299; *Gene Transfer to Plants* (1995), Potrykus, I. and Spangenberg, G. eds. Springer -Verlag Berlin Heidelberg New York. and "Transgenic Plants: A Production System for Industrial and Pharmaceutical Proteins" (1996), Owen,  
30    M.R.L. and Pen, J. eds. John Wiley & Sons Ltd. England) all of which are incorporated herein by reference. U.S. Patent No. 5,610,041 describes plastid expression by adding a leader peptide to direct the

protein expressed from the nuclear gene to the plastid. More recent technology enables the direct insertion of foreign genes directly into the plastid chromosome by recombination (Svab et. al., 1990, Proc. Natl. Acad. Sci. USA. 87: 8526-8530; McBride et. al., 1994, Proc. Natl. Acad. Sci. USA. 91: 7301-7305). The prokaryotic nature of the plastid RNA and protein synthesis machinery also allows for the expression of microbial operons such as for example the *phbCAB* operon of *A. eutrophus*. This technology allows for the direct incorporation of a series of genes encoding a multi-enzyme pathway into the plastid genome. It is also important to take into account the importance of 5'-untranslated regions of plastid genes for mRNA stability and translation (Hauser et. al., 1996. J. Biol. Chem. 271: 1486-1497). In some cases it may be useful to re-engineer the 5'-untranslated regions, remove secondary structure elements, or add elements from highly expressed plastid genes to maximize expression of transgenes encoded by an operon.

We claim:

1. A recombinant host having stably incorporated into the genome a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 4HB-CoA transferase.
2. The host of claim 1 having stably incorporated into its genome both a polyhydroxyalkanoate synthase and a 4HB-CoA transferase.
3. The host of claim 1 wherein the host is *E. coli*.
4. The host of claim 3 wherein the heterologous enzyme is a polyhydroxyalkanoate synthase and the host expresses an endogenous enzyme with 4HB-CoA transferase activity.
5. The host of claim 1 further comprising genes expressing enzymes selected from the group consisting of  $\beta$ -ketothiolase and acetoacetyl Co reductase.
6. A method for enhancing production of polymers containing 4HB in a host comprising  
stably incorporating into the genome of the host a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 4HB-CoA transferase.
7. The method of claim 6 wherein the host has stably incorporated into its genome both a polyhydroxyalkanoate synthase and a 4HB-CoA transferase.
8. The method of claim 6 further comprising enhancing expression of the heterologous enzyme.
9. The method of claim 8 wherein expression is enhanced by mutating the host followed by providing 4HB as a substrate and screening for polymer production by the mutated host.
10. The method of claim 6 further comprising providing a host expressing enzymes selected from the group consisting of  $\alpha$ -ketoglutarate transaminase, glutamate-succinic semialdehyde transaminase, glutamate dehydrogenase, glutamate decarboxylase, 4-hydroxybutyrate dehydrogenase and 4-hydroxybutyryl CoA transferase.

11. The method of claim 6 further comprising providing a host expressing enzymes degrading arginine, glutamine or proline to produce gamma amino butyric acid.
12. A 4HB polymer produced by a recombinant host having stably incorporated into the genome a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 4HB-CoA transferase.
13. A vector comprising an isolated gene encoding a 4HB-CoA transferase under the control of a promoter for enhancing expression after integration into the genome of a heterologous host.

OrfZ 1 MEWEEIYKEKLVTAEKAVSKIENHSRVVFAHAVGEPVDLVNALVKNKDNYIGLEIVHMVA  
M\*W IY \*\*  
4HBCT MDWKKIYEDRT

OrfZ 61 MGKGVYTKEGMQRHFHNALEFVGSTRDAVNSGRAVYTPCFEYVPSLFEKEKRLPVDVAL  
OrfZ 121 IQVSEPDKYGYCSFGVSNDYTKPAESAELVIAEVNKNMPRTLGDSEFIHVSDIDYIVEAS  
OrfZ 181 HPLELQPPKLGDVKAIGENCASLIEDGATLQLGIGAI PDAVLLFLKNKKNLGIHSEMI  
OrfZ 241 SDGVMELVKAGVINNNKKKTLHPGKIVVTFILMGTKKLYDFVNNNPMVETYSVDYVNNPLVI  
OrfZ 301 MKNDNMVSINSCVQVDLMGQVCSESIGLKQISGVGGQVDFIRGANLSKGGKAIIPSTA  
AIIA PS A  
4HBCT AIIAMPSVA

1/14

OrfZ 361 GKGVSRITPLLDTGAAVTTSRNEVDYVVTEYGVVHLKGTLRNRRARALINIAHPKFRES  
N\*\*DYVVTEYG A K ALINIAHP F\*\*  
4HBCT K NDADYVVTEYGI AEMK ALINIAHPDFKDE

OrfZ 421 LMNEFKKRF  
L  
4HBCT LK

FIG. 1A

2/14

*FIG. 1B*

The sequence of the orfZ gene from *C. kluyveri* is:  
ATGGAGTGGGAAGAGATATATAAAGAGAACTGGTAACCTGCAGAAAAGCTGT  
TTCAAAAATAGAAAACCATAGCAGGGTAGTTTTTGCACATGCAGTAGGAGAACCC  
CGTAGATTTAGTAAATGCACCTAGTTAAAAATAAGGATAATTATATAGGACTAGA  
AATAGTTCACATGGTAGCTATGGGCAAAAGGTGTATATACAAAAGAGGGTATGC  
AAAGACATTTTAGACATAATGCTTTGTTGTAGCGGATCTACTAGAGATGCAG  
TAAATTCAGGAAGAGCAGTTTATACACCTTGTTTTTCTATGAAGTGCCAAAGTTT  
GTTTAAAGAAAACGTTTGCCGTAGATGTAGCACTTATTCAGGTAAGTGAGCC  
AGATAAATATGGCTACTGCAGTTTGGAGTTTCCAAATGACTATACCAAGCCAGC  
AGCAGAAAAGTGCTAAGCTTGTAATTGCAGAAGTGAATAAAAACATGCCAAGAA  
CTCTTGGAGATTCTTTATACATGTATCAGATATTGATTATATAGTGAAGCTTC  
ACACCCATTGTTAGAATTGCAGCCTCCTAAATTGGGAGATGTAGAAAAGCCAT  
AGGAGAAAACCTGTGCATCTTTAATTGAAGATGGAGCTACTCTTCAGCTTGGAAT  
AGGTGCTATACCAAGATGCGGTACTTTTATTCTTAAAGAACAAAAGAAATTTAGG  
AATACATTCTGAGATGATATCAGATGGTGTGATGGAACTGGTGAAGGCAGGGG  
TTATCAATAACAAGAAAAGACCCCTCCATCCAGGCAAAATAGTTGTAAACATTTT

FIG. 1C

AATGGGAACAAAAATTATATGATTTTGTAACAATAATCCAATGGTAGAAAC  
TTATTCTGTAGATTATGTAAATAATCCACTGGTAATTATGAAAAATGACAAATATG  
GTTCAATAAATTCTTGTTCAAGTAGACTTAATGGGACAAAGTATGTTCTGAAA  
GTATAGGATTGAAACAGATAAGTGGAGTGGAGGCCAGGTAGATTTTATTAGA  
GGAGCTAATCTATCAAGGGTGGAAAGGCTATTATAGCTATACCTTCCACAGCT  
GGAAAAGGAAAAGTTTCAAGAAATAACTCCACTTCTAGATACTGGTGTGCAGTT  
ACAACTTCTAGAAATGAAGTAGATTATGTAGTTACTGAATATGGTGTGCTCATC  
TTAAGGGCAAACTTTAAGAAATAGGGCAAGAGCTCTAATAAATATCGCTCATC  
CAAAATTCAGAGAATCATTAATGAATGAATTTAAAAAGAGATTTTAG

*FIG. 1D*

The sequence of the orfZ gene product is:

MEWEEIYKEKLVTAEKAVSKIENHSRVVFAHAVGEPVDLVNALVKNKNDNYIGLEI  
VHMVAMGKGVYTKEGMQRHFERNALFVGGSTRDAVNSGRAVYTPCFYEVPSL  
FKEKRLPVDVALIQVSEPDKYCYCSFGVSNDYTKPAAESAKLVIAEVNKNMPRTL  
GDSFIHVSDIDYIVEASHPLLELQPPKLG DVEKAIGENCASLIEDGATLQLGIGAIPD  
AVLLFLKNKNLGIHSEMI SDGVMELVKAGVINNNKKKTLHPGKI VVTFILMGTKK  
LYDFVNNPMVETYSVDYVNNPLVIMKNDNMV SINSVCVQVDLMGQVCSESIGLK  
QISGVGGQVDFIRGANLSKGGKAILAIPSTAGKGVSRITPLD TGAAVTTSRNEVD  
YVVTEYGV AHLKGKTLRNRARALINIAHPKFRESLMNEFKKRF\*

Neither the sequence of the hbct gene from C.  
aminobutyricum nor the complete amino acid sequence of the  
corresponding enzyme is known.

5/14





FIG. 2

6/14








FIG. 4

8/14




9/14

FIG. 6



10/14

FIG. 6A



11/14





FIG. 7

FIG. 8



12/14




FIG. 10




FIG. 11

